UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
33.48
-0.27 (-0.80%)
At close: Oct 29, 2026, 4:00 PM EDT
32.55
-0.93 (-2.78%)
After-hours: Oct 29, 2026, 7:30 PM EDT
UroGen Pharma Revenue
UroGen Pharma had revenue of $72.46M in the quarter ending June 30, 2026, with 199.22% growth. This brings the company's total for the last twelve months to $188.73M, up 100.27% year-over-year. In the year 2025, UroGen Pharma had annual revenue of $109.79M with 21.45% growth. That makes UroGen Pharma the 17,876th largest company in the world by revenue and 2,913th in the United States.
Revenue (ttm)
$188.73M
Revenue Growth
+100.27%
P/S Ratio
8.67
Revenue / Employee
$629,113
Employees
300
Market Cap
1.64B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 109.79M | 19.39M | 21.45% |
| Dec 31, 2024 | 90.40M | 7.69M | 9.29% |
| Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
| Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
| Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
| Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
| Dec 31, 2019 | 18.00K | -1.11M | -98.40% |
| Dec 31, 2018 | 1.13M | -7.03M | -86.17% |
| Dec 31, 2017 | 8.16M | -9.37M | -53.46% |
| Dec 31, 2016 | 17.53M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 717.00M |
| Immunocore Holdings | 430.78M |
| Novavax | 413.80M |
| Intellia Therapeutics | 59.51M |
| Stoke Therapeutics | 27.59M |
| Generate Biomedicines | 26.48M |
| uniQure | 18.67M |
| Nanobiotix | 13.15M |
URGN News
- 1 day ago - UroGen's Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer - GlobeNewsWire
- 2 days ago - UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026 - GlobeNewsWire
- 10 days ago - UroGen Pharma announces FDA acceptance of UGN-103 NDA - TheFly
- 10 days ago - UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC - GlobeNewsWire
- 15 days ago - UroGen Pharma management to meet with Oppenheimer - TheFly
- 21 days ago - UroGen Pharma falls -12.8% - TheFly
- 5 weeks ago - UroGen Pharma management to meet with Piper Sandler - TheFly
- 6 weeks ago - UroGen Pharma Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts